This 6.5%‑Yielding Dividend Payer is Sitting on a Breakthrough Investors Haven't Priced In24/7 Wall Street • 03/25/26
Pfizer: Undervalued High-Yield Giant With A Pipeline Built For The Next DecadeSeeking Alpha • 03/25/26
Pfizer Could Hit $36 by Year-End as Analysts See 2-to-1 Payoff on Key Prostate Cancer Trial24/7 Wall Street • 03/24/26
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with AnalystsBusiness Wire • 03/24/26
An experimental Lyme disease vaccine from Pfizer and Valneva was effective at preventing the tick-borne disease in a new clinical trial but the findings aren't conclusiveWSJ • 03/23/26
Pfizer and French partner to seek approval for Lyme disease vaccine after late-stage trialMarket Watch • 03/23/26
Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR TrialBusiness Wire • 03/23/26
PFE Talzenna Combo Shows Strong Efficacy in Wider Prostate Cancer UseZacks Investment Research • 03/20/26
TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate CancerBusiness Wire • 03/19/26
PFE's Atirmociclib 2L Breast Cancer Study Hits Goal, Aid Pipeline PushZacks Investment Research • 03/18/26